Literature DB >> 15279598

Advance in understanding the biosynthesis of prostacyclin and thromboxane A2 in the endoplasmic reticulum membrane via the cyclooxygenase pathway.

Ke-He Ruan1.   

Abstract

Recent advances in topological and structural characterization of the prostacyclin (PGI(2)) and thromboxane A(2) (TXA(2)) synthases have led to the understanding of the biosynthesis of PGI(2) and TXA(2) at a structural level. This mini-review focuses on the molecular mechanism of the isomerization of the prostaglandin H(2) to PGI(2)and TXA(2) by their synthases in the endoplasmic reticulum (ER) membrane coordinated with cyclooxygenase-1 or -2. This review summarizes the evidences in which the biosynthesis of PGI(2)and TXA(2) are influenced/modulated by the membrane anchor residues of the synthases and the ER membrane itself, and provides the structural basis for engineering the synthases for the next generation of gene therapy and drug designs targeting the specific synthases.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15279598     DOI: 10.2174/1389557043403710

Source DB:  PubMed          Journal:  Mini Rev Med Chem        ISSN: 1389-5575            Impact factor:   3.862


  13 in total

1.  Inducible COX-2 dominates over COX-1 in prostacyclin biosynthesis: mechanisms of COX-2 inhibitor risk to heart disease.

Authors:  Cheng-Huai Ruan; Shui-Ping So; Ke-He Ruan
Journal:  Life Sci       Date:  2010-10-28       Impact factor: 5.037

Review 2.  Drug treatment of pulmonary hypertension in children.

Authors:  Erika E Vorhies; David Dunbar Ivy
Journal:  Paediatr Drugs       Date:  2014-02       Impact factor: 3.022

Review 3.  Prostacyclin therapy for pulmonary arterial hypertension.

Authors:  Cheng-Huai Ruan; Richard A F Dixon; James T Willerson; Ke-He Ruan
Journal:  Tex Heart Inst J       Date:  2010

Review 4.  The role of prostaglandins in allergic lung inflammation and asthma.

Authors:  Dru Claar; Tina V Hartert; Ray Stokes Peebles
Journal:  Expert Rev Respir Med       Date:  2014-12-26       Impact factor: 3.772

5.  Engineering of a novel hybrid enzyme: an anti-inflammatory drug target with triple catalytic activities directly converting arachidonic acid into the inflammatory prostaglandin E2.

Authors:  Ke-He Ruan; Vanessa Cervantes; Shui-Ping So
Journal:  Protein Eng Des Sel       Date:  2009-10-22       Impact factor: 1.650

Review 6.  Pediatric Cardiac Intensive Care Society 2014 Consensus Statement: Pharmacotherapies in Cardiac Critical Care Pulmonary Hypertension.

Authors:  John S Kim; Julia McSweeney; Joanne Lee; Dunbar Ivy
Journal:  Pediatr Crit Care Med       Date:  2016-03       Impact factor: 3.624

Review 7.  Prostaglandins in asthma and allergic diseases.

Authors:  R Stokes Peebles
Journal:  Pharmacol Ther       Date:  2018-08-03       Impact factor: 12.310

Review 8.  Drug Treatment of Pulmonary Hypertension in Children.

Authors:  Catherine M Avitabile; Erika E Vorhies; David Dunbar Ivy
Journal:  Paediatr Drugs       Date:  2020-04       Impact factor: 3.022

9.  Engineering 'Enzymelink' for screening lead compounds to inhibit mPGES-1 while maintaining prostacyclin synthase activity.

Authors:  Diana T Ruan; Nanhong Tang; Hironari Akasaka; Renzhong Lu; Ke-He Ruan
Journal:  Future Med Chem       Date:  2021-06-03       Impact factor: 4.767

Review 10.  The Roles of Various Prostaglandins in Fibrosis: A Review.

Authors:  Ke Li; Jing Zhao; Mingxuan Wang; Lingzhi Niu; Yuanping Wang; Yanxia Li; Yajuan Zheng
Journal:  Biomolecules       Date:  2021-05-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.